With its lead asset in the clinic to assess its effectiveness to prevent Clostridium difficile (C. diff) infection (CDI), Finch Therapeutics Inc. looked two miles down the road and took a calculated step to expand its presence in the microbiome field, orchestrating a merger with neighboring Crestovo LLC, whose phase II CDI asset, CP-101, was deemed superior.